Sector News

Jazz hiring 100-plus sales representatives to prep for new launches

August 21, 2018
Life sciences

Jazz Pharmaceuticals is closing in on two new approvals, one on each side of the Atlantic, and it’s staffing up to hit the ground running on both launches.

Chief operating officer Dan Swisher said Jazz is adding 100 sales representatives in the U.S. for the expected approval of solriamfetol, a candidate to treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea. Although that figure won’t double the company’s sales force, it’s a “significant expansion” for the drugmaker, which is approaching $2 billion in sales this year. Jazz is also studying the use of solriamfetol in other conditions where excessive sleepiness is a problem, including Parkinson’s disease and multiple sclerosis.

Jazz has hired a full brand team for the rollout of solriamfetol, which it expects to become a significant addition to its portfolio with eventual sales of $500 million. Right now, it’s running a pre-launch disease awareness campaign targeted at healthcare professionals (HCPs) but expects to take marketing directly to consumers down the road.

“We’ve got this broad-based disease awareness campaign going to healthcare professionals. We look forward to having a more drug-specific awareness campaign coming later, and then obviously a lot of healthcare provider promotion, and then at the right point, activating consumers,” Swisher said.

Meanwhile, Jazz has bumped its European field force of sales and medical to 80 from 50, with the expected European approval for Vyxeos as a first-line treatment for secondary acute myeloid leukemia next month. The drug was approved in the U.S. last August, and Swisher characterized the U.S. rollout as “going well” with a dedicated field force of 30 and anticipated sales of $120 million expected this year.

Jazz employs 1,200 people globally with corporate headquarters in Dublin and U.S. headquarters in Palo Alto, Calif. Swisher joined Jazz in January after 17 years at Sunesis Pharmaceuticals where he was president and CEO.

Jazz is, of course, still pushing on its bread-and-butter narcolepsy drug Xyrem, which has about 14,000 patients on treatment. Its target market is lots bigger: 60,000 patients already diagnosed and another estimated 60,000 who are undiagnosed, Swisher said. A recent narcolepsy awareness promotion with HCPs led to “near double-digit growth in new starts,” he said.

Jazz has its eyes on even broader use, too. Xyrem is up for a new approval in pediatric patients, and Jazz is hoping to roll out the drug for kids next year. It’s also pursuing a low-sodium version of Xyrem which currently has very high levels, a fact that’s noted by physicians as an issue in prescribing.

Jazz is pushing innovations and marketing around Xyrem as it faces a slew of upcoming generics, with eight tentatively approved by the FDA to date. With patent litigation now settled, the first Xyrem generic is expected to come to market in 2023.

By Beth Snyder Bulik

Source: Fierce Pharma

comments closed

Related News

November 19, 2022

Sequana announces results from study of direct sodium removal

Life sciences

Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients confirmed long-lasting clinical benefits.

November 19, 2022

Bristol Myers Squibb opens 125-acre biologics campus in Dublin

Life sciences

Bristol Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, which represents a $1bn investment – was officially opened by the company’s chief executive officer, Giovanni Caforio, who arrived from New York, and site general manager Pádraig Keane.

November 19, 2022

Pharma must stay the course on Twitter as docs are not abandoning the platform yet: Report

Life sciences

Like it or loathe it, and whatever its new direction, Twitter is still a powerful platform for doctors, and pharma should not abandon the troubled social media site yet, according to a new report from healthcare consultants at ZoomRx.